Regulatory Requirements for Hearing Aid Devices and Personal Sound Amplification Products

Guidance for Industry and Food and Drug Administration Staff

Document issued on August 17, 2022.

The draft of this document was issued on October 20, 2021.

This document supersedes “Guidance for Industry and FDA Staff: Regulatory Requirements for Hearing Aid Devices and Personal Sound Amplification Products” issued February 25, 2009.

For questions about this document, contact OHT1: Office of Ophthalmic, Anesthesia, Respiratory, ENT and Dental Devices/DHT1B: Division of Dental and ENT Devices/THT1B3: ENT Devices Team at 301-796-5620.
Preface

Public Comment

You may submit electronic comments and suggestions at any time for Agency consideration to https://www.regulations.gov. Submit written comments to the Dockets Management Staff, Food and Drug Administration, 5630 Fishers Lane, Room 1061, (HFA-305), Rockville, MD 20852. Identify all comments with the docket number FDA-2020-D-1380. Comments may not be acted upon by the Agency until the document is next revised or updated.

Additional Copies

Additional copies are available from the Internet. You may also send an email request to CDRH-Guidance@fda.hhs.gov to receive a copy of the guidance. Please include the document number 1832 and complete title of the guidance in the request.
Table of Contents

I. Introduction ........................................................................................................................................ 4
II. Background ....................................................................................................................................... 5
III. Definitions and Scope ..................................................................................................................... 5
IV. Regulatory Requirements .................................................................................................................. 7
   A. Hearing Aids .................................................................................................................................. 7
   B. Personal Sound Amplification Products (PSAPs) ......................................................................... 8
   C. Distinction between PSAPs and Hearing Aids .......................................................................... 9
Regulatory Requirements for Hearing Aid Devices and Personal Sound Amplification Products

Guidance for Industry and Food and Drug Administration Staff

This guidance represents the current thinking of the Food and Drug Administration (FDA or Agency) on this topic. It does not establish any rights for any person and is not binding on FDA or the public. You can use an alternative approach if it satisfies the requirements of the applicable statutes and regulations. To discuss an alternative approach, contact the FDA staff or Office responsible for this guidance as listed on the title page.

I. Introduction

This guidance document identifies applicable legal requirements under the Federal Food, Drug, and Cosmetic Act (the FD&C Act) for hearing aids and for personal sound amplification products (PSAPs). Hearing aids and PSAPs both affect a user’s ability to hear sound, but the products have different intended uses, and are therefore subject to different regulatory controls. Unlike hearing aids which are intended to aid a person with or compensate for hearing impairment, PSAPs (as defined in Section III) are not intended to diagnose, treat, cure, mitigate, or prevent disease and are not intended to affect the structure or function of the body. Therefore, they are not considered to be “devices” as defined in the FD&C Act.¹

A lack of clarity between PSAPs and hearing aids has contributed to stakeholder and consumer confusion. This guidance is intended to describe hearing aids, PSAPs, their respective intended uses, and the regulatory requirements that apply to both types of products.

The contents of this document do not have the force and effect of law and are not meant to bind the public in any way, unless specifically incorporated into a contract. This document is intended only to provide clarity to the public regarding existing requirements under the law. FDA guidance documents, including this guidance, should be viewed only as recommendations, unless specific regulatory or statutory requirements are cited. The use of the

¹ See section 201(h) of the FD&C Act (21 U.S.C. 321(h)).
word *should* in Agency guidance means that something is suggested or recommended, but not required.

II. Background

The FDA Reauthorization Act of 2017 (FDARA) (Pub. L. 115-52) directs FDA to establish a category of over-the-counter (OTC) hearing aids through rulemaking, and mandates that FDA establish various requirements for this category of devices. FDA has finalized a rule to establish the OTC category of hearing aids and implement the requirements of FDARA (“Rule”). In this Rule, FDA made multiple related changes to the overall regulatory framework for hearing aids to harmonize existing regulations with the OTC category while continuing to provide reasonable assurance of safety and effectiveness. Specifically, this Rule defines OTC hearing aids and establishes applicable requirements; amends existing rules for consistency with the new OTC category, and these amended rules apply to most other hearing aids which are now regulated as prescription devices (21 CFR 801.422); repeals the conditions for sale that were applicable to hearing aids under 21 CFR 801.421; and updates regulations relating to decisions on applications for exemption from Federal preemption that are obsolete as a result of changes to the hearing aid requirements. This guidance references the citations set forth in the Rule (e.g., 21 CFR 800.30).

FDARA also directed FDA to update and finalize the draft guidance entitled “Regulatory Requirements for Hearing Aid Devices and Personal Sound Amplification Products,” issued on November 7, 2013. In order to fulfill this FDARA requirement, FDA updated the November 7, 2013 draft guidance by issuing a draft guidance on October 20, 2021. This guidance finalizes the 2021 draft guidance and supersedes the February 25, 2009 guidance. The Rule creates a heightened need to appropriately inform consumers by clearly distinguishing PSAPs from OTC hearing aids from a regulatory standpoint. This guidance is intended to accomplish that goal. We intend to continue to take a risk-based approach to enforcing our regulations to protect the public health.

FDA provides additional information regarding hearing aids on the following website: [https://www.fda.gov/medical-devices/consumer-products/hearing-aids](https://www.fda.gov/medical-devices/consumer-products/hearing-aids).

III. Definitions and Scope

A hearing aid is “any wearable device designed for, offered for the purpose of, or represented as aiding persons with or compensating for, impaired hearing” (21 CFR 800.30(b) and 21 CFR 801.422(b)). This definition encompasses both air-conduction and bone-conduction devices in a variety of styles (e.g., behind-the-ear, in-the-canal, body worn). Hearing aids are devices as

---


3 See FDARA section 709(c) (Pub. L. 115-52, 131 Stat. 1067).
defined by section 201(h) of the FD&C Act. Hearing aids do not include cochlear implants or implantable middle ear hearing devices, which are class III devices that require an approved premarket approval (PMA) application before marketing (section 513(a) of the FD&C Act). In contrast, an electronic product that is intended for non-hearing impaired consumers to amplify sounds in certain environments, such as for hunting or other recreational activities, and is not intended to aid persons with or compensate for impaired hearing, is considered a PSAP. Such PSAPs are not devices as defined in section 201(h) of the FD&C Act and therefore, are not regulated as such.

Currently, hearing aid devices may be classified as:

- class I devices, exempt from premarket notification (510(k)) (21 CFR 874.3300);
- class II devices, which require premarket notification (510(k)) and compliance with special controls (if applicable to the specific regulation) before marketing (21 CFR 874.3302, 21 CFR 874.3315, 21 CFR 874.3325, and 21 CFR 874.3950); or
- class II devices that are exempt from premarket notification (510(k)), subject to required special controls (21 CFR 874.3305).

Product codes for the various types of devices under these classification regulations are listed in Table 1:

---

4 A device is an instrument, apparatus, implement, machine, contrivance, implant, in vitro reagent, or other similar or related article, including any component, part, or accessory, intended for use in the diagnosis of disease or other conditions, or in the cure, mitigation, treatment, or prevention of disease, in man or other animals, or intended to affect the structure or any function of the body of man or other animals, and which does not achieve its primary intended purposes through chemical action within or on the body of man or other animals and which is not dependent upon being metabolized for the achievement of its primary intended purposes. The term "device" does not include software functions excluded pursuant to section 520(o). See section 201(h) of the FD&C Act (21 U.S.C. 321(h)).

5 The term “electronic product” means (A) any manufactured or assembled product which, when in operation, (i) contains or acts as part of an electronic circuit and (ii) emits (or in the absence of effective shielding or other controls would emit) electronic product radiation, or (B) any manufactured or assembled article which is intended for use as a component, part, or accessory of a product described in clause (A) and which when in operation emits (or in the absence of effective shielding or other controls would emit) such radiation. See section 531(2) of the FD&C Act (21 U.S.C. 360hh(2)).

6 Tactile hearing aids, under product code LRA, are currently unclassified devices, subject to premarket notification (510(k)). They are a preamendments device type and do not have a classification regulation.

7 Refer to 21 CFR 874.9 for the limitations of exemptions from 510(k).

8 Ibid.

9 In accordance with 21 CFR 874.9, an air-conduction hearing aid device under 21 CFR 874.3300 and a wireless air-conduction hearing aid under 21 CFR 874.3305 are exempt from premarket notification unless the device: 1) is intended for a use different from the intended use of a legally marketed device of that generic type, or 2) if the device operates using a different fundamental scientific technology than a legally marketed device of that generic type.
Table 1 – Relevant Product Codes

<table>
<thead>
<tr>
<th>Regulation Number</th>
<th>Product Code and Name</th>
</tr>
</thead>
<tbody>
<tr>
<td>21 CFR 874.3300</td>
<td>LRB (Face Plate Hearing Aid)</td>
</tr>
<tr>
<td>21 CFR 874.3300</td>
<td>ESD (Hearing Aid, Air Conduction)</td>
</tr>
<tr>
<td>21 CFR 874.3300</td>
<td>LDG (Kit, Earmold, Impression)</td>
</tr>
<tr>
<td>21 CFR 874.3302</td>
<td>LXB (Hearing Aid, Bone Conduction)</td>
</tr>
<tr>
<td>21 CFR 874.3302</td>
<td>MAH (Hearing Aid, Bone Conduction, Implanted)</td>
</tr>
<tr>
<td>21 CFR 874.3305</td>
<td>OSM (Hearing Aid, Air Conduction with Wireless Technology)</td>
</tr>
<tr>
<td>21 CFR 874.3315</td>
<td>PLK (Tympanic Membrane Direct Contact Hearing Aid)</td>
</tr>
<tr>
<td>21 CFR 874.3325</td>
<td>QDD (Self-Fitting Air-Conduction Hearing Aid)</td>
</tr>
<tr>
<td>21 CFR 874.3950</td>
<td>NIX (Hearing Aid, Air Conduction, Transcutaneous System)</td>
</tr>
</tbody>
</table>

Although the product codes listed above are current as of the date of issuance of this guidance, new product codes may be created over time for hearing aids regulated under the classification regulations identified above and would fall within the scope of this guidance. We recommend that you reference the product code database (http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfPCD/classification.cfm) if you are unsure whether this guidance applies to your device and the product code for your device is not already captured in this guidance.

Although the Rule amends the classification regulations for hearing aids, this does not impact the scope of this guidance. This final guidance aligns and is consistent with the Rule.

This guidance does not apply to the group hearing aid or group auditory trainer (21 CFR 874.3320), master hearing aid (21 CFR 874.3330), and tinnitus masker (21 CFR 874.3400).

IV. Regulatory Requirements

As discussed in Section III, hearing aids are devices under section 201(h) of the FD&C Act and PSAPs (as defined in Section III) are not devices as defined by section 201(h) and therefore, are not regulated as such. This section provides further clarity regarding the intended uses of hearing aids and PSAPs and the regulatory requirements for both types of products.

A. Hearing Aids

As devices, hearing aids are subject to applicable device requirements under the FD&C Act and FDA regulations (e.g., adverse event reporting). FDA regulations also include specific requirements for hearing aids, such as labeling, that are further discussed below. Hearing aids are also electronic products, and therefore, are subject to applicable electronic product requirements under the FD&C Act and FDA regulations (these requirements are discussed in the PSAP section below).
FDA’s regulation of OTC and prescription hearing aids is intended to provide consumers access to safe and effective hearing aids and ensure that consumers understand how to use available technology and understand when to seek an evaluation by a qualified professional. Specific information in hearing aid labeling is essential in order for consumers or hearing aid dispensers to identify conditions that either may pose a threat to health if left undiagnosed, or avoid unnecessary and inappropriate hearing aid use (e.g., cerumen (earwax) impaction). Specific information in hearing aid labeling will also help consumers and hearing aid dispensers choose appropriate hearing aids that are safe and effective for the consumer’s hearing condition. Equipped with this information, consumers can better decide how to address their needs among all options available to them.

The Rule requires OTC hearing aids, as defined therein, to comply with the requirements for OTC hearing aids (21 CFR 800.30), which include, among others, labeling, performance, and design requirements, in addition to other applicable requirements, including but not limited to special controls found in the applicable classification regulation. Hearing aids that meet the definition of, and satisfy the requirements for, OTC hearing aids, are considered “available” over the counter as specified in section 520(q)(1)(A)(v) of the FD&C Act. Any hearing aid that does not meet the definition of an OTC hearing aid or satisfy the requirements of 21 CFR 800.30 will be a prescription device.  

The Rule also repeals the conditions for sale in 21 CFR 801.421 and amends the labeling requirements in 21 CFR 801.420 (by moving them to 21 CFR 801.422, limiting their scope to prescription hearing aids, and revising them as appropriate to provide consistency with the new labeling requirements for OTC hearing aids in 21 CFR 800.30). Thus, prescription hearing aids must comply with the hearing aid specific requirements in 21 CFR 801.422 in addition to other applicable requirements, including but not limited to special controls found in the applicable classification regulation.

B. Personal Sound Amplification Products (PSAPs)  
This subsection describes PSAPs that fall within the definition provided in Section III of this document. PSAPs are not intended to compensate for hearing impairment. They are intended to accentuate sounds in specific listening environments for non-hearing impaired listeners. Because PSAPs are not intended to diagnose, treat, cure, mitigate, or prevent disease and are not intended to affect the structure or function of the body, they are not devices as defined in the FD&C Act. As such, there is no regulatory classification or product code for these products. Furthermore, there are no requirements for registration of manufacturers or listing of these products with FDA. However, PSAPs are subject to applicable provisions of the Radiation Control for Health and

10 See 21 CFR 801.422.
11 Previously, all hearing aids were subject to required conditions for sale provided in 21 CFR 801.421. FDA’s guidance, “Conditions for Sale for Air-Conduction Hearing Aids,” issued on December 12, 2016, described the Agency’s previous enforcement policy with respect to the conditions for sale. FDA withdrew this guidance on October 17, 2022. See https://www.fda.gov/medical-devices/guidance-documents-medical-devices-and-radiation-emitting-products/withdrawn-guidance.
12 See section 201(h) of the FD&C Act (21 U.S.C. 321(h)).
Safety Act of 1968, under which FDA regulates electronic products that emit sonic vibrations, such as sound amplification equipment. Manufacturers of PSAPs must report accidental radiation occurrences under 21 CFR Part 1002, and report defects and take other measures described in 21 CFR Part 1003. Manufacturers of PSAPs must also comply with the requirements to repurchase, repair, or replace electronic products under 21 CFR Part 1004.

Examples of situations in which PSAPs typically are used include hunting (listening for prey), bird watching, listening to lectures with a distant speaker, and listening to soft sounds that would be difficult for normal hearing individuals to hear (e.g., distant conversations).

C. Distinction between PSAPs and Hearing Aids

FDA is aware of confusion in the marketplace over what FDA considers a hearing aid and what it considers a PSAP. While the technology of hearing aids and PSAPs may be similar, FDA considers the intended use of each product to determine whether it is a device or solely an electronic product. A product’s intended use refers to the “objective intent” of those legally responsible for the labeling of the product, which may be shown by their oral or written expressions, the design or composition of the product, or by the circumstances surrounding the distribution of the product. This objective intent may be shown, for example, by the claims made in product labeling or advertising, and from other relevant sources. Accordingly, FDA may consider, among other things, any written or oral claims or statements in any label, labeling, advertising, and/or promotion of a product by or on behalf of a firm in determining whether a product is a device.

Explicitly or implicitly claiming or stating that a product addresses, mitigates, or improves hearing loss/impaired hearing would be considered an intent to diagnose, treat, cure, mitigate, or prevent disease or to affect the structure or function of the body. The following are examples of explicit or implicit claims or statements that FDA believes would generally cause the product to meet the device definition, in which case the product would be subject to the regulatory requirements applicable to devices, including the specific requirements applicable to hearing aids, as discussed above in this guidance:

- suggestions that the product is for users with certain types or severity of hearing loss/impaired hearing;
- suggestions that the product is indicated for use in situations that are typically associated with and indicative of hearing loss/impaired hearing;

---

14 See 21 CFR 1000.15(d).
15 See 21 CFR 801.4.
16 See id.
17 “Labeling” is defined in section 201(m) of the FD&C Act (21 U.S.C. 321(m)) as “all labels and other written, printed, or graphic matter (1) upon any article or any of its containers or wrappers, or (2) accompanying such article.” Labeling may include promotional materials.
18 For the purposes of this guidance document, the term “firm” is used to refer to “persons legally responsible for the labeling of an article (or their representatives)” under 21 CFR 801.4.
Contains Nonbinding Recommendations

- suggestions that the product is an alternative to a hearing aid (PSAPs are not considered “over-the-counter” alternatives or substitutes for a hearing aid), for example, marketing it as a less expensive alternative to hearing aids or marketing it to consumers who may have hearing loss/impaired hearing and are not yet ready to buy hearing aids;
- information conveyed to the user to optimize the product to their hearing loss/impaired hearing profile (e.g., providing hearing thresholds or a measure of hearing loss/impaired hearing, or using a hearing aid fitting formula or other algorithms to program the product output to match the user’s hearing loss/impaired hearing profile).